Targeting tau to treat Alzheimer’s disease
This article was originally published in Start Up
Oligomerix Inc. is increasingly confident that small aggregates of the protein tau are a key culprit in the progression of Alzheimer’s disease. It aims to inhibit tau oligomer formation or self-association, the initial steps in aggregation of the protein, and thereby interrupt the disease process at a relatively early juncture.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.